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Fluoroquinolone-Resistant Streptococcus agalactiae
Invasive Isolates Recovered in Argentina
Bárbara Arias,1 Verónica Kovacec,1 Laura Vigliarolo,2 Mariana Suárez,2 Carina Tersigni,2 Loana Müller,1
Horacio Lopardo,2 Laura Bonofiglio,1,3 and Marta Mollerach1,3
Background: Streptococcus agalactiae or group B Streptococcus (GBS) is an important pathogen in neonates
and nonpregnant individuals. Epidemiological studies of GBS resistance to fluoroquinolones (FQs) in Latin
America are scarce. This study aimed to determine the local prevalence of FQ resistance in the frame of a
national, prospective multicenter study of invasive GBS infections and to investigate mechanisms of resistance,
serotype distribution, and clonal relationships among resistant isolates.
Methods: From July 2014 to July 2015, 162 invasive GBS isolates were collected from 86 health care centers in
32 Argentinean cities. All isolates were screened for FQ nonsusceptibility using a five-disc scheme: levo-
floxacin (LVX), ciprofloxacin, norfloxacin (NOR), ofloxacin, and pefloxacin (PF). LVX minimal inhibitory
concentration (MIC) was determined by the agar dilution method. Sequencing of internal regions of gyrA and
parC genes was performed. Capsular typing and genetic characterization of nonsusceptible isolates were
assessed by latex agglutination, pulsed-field gel electrophoresis (PFGE), and multilocus sequence typing.
Results: Twenty-four of one hundred sixty-two GBS isolates exhibited no inhibition zones to all tested FQs
with an MIC range of 16–32 mg/L for LVX, and one isolate with MIC = 1 mg/L showed no inhibition zones
around NOR and PF discs. In all resistant isolates, point mutations were detected in both genes. Serotype Ib was
prevalent (88%). One PFGE type accounted for 84% of the FQ-resistant isolates and belonged to serotype Ib,
sequence type 10.
Conclusions: The prevalence of FQ resistance was 14.8% likely to be associated with dissemination of an
ST10/serotype Ib clone. The unexpected high rate of resistance emphasizes the relevance for continuous
surveillance of GBS epidemiology and antibiotic susceptibility.
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Introduction
Streptococcus agalactiae or group B Streptococcus(GBS) is the leading cause of neonatal sepsis and men-
ingitis and it has been recognized as an important pathogen in
nonpregnant individuals, especially elderly people and those
suffering from underlying medical disorders.1,2
Penicillin (PEN) remains the first choice to treat GBS
infections, although strains with reduced susceptibility to
this antibiotic have been recently described.3,4 Alternative
therapies are the use of macrolides and lincosamides; unfor-
tunately, resistance to this class of antibiotics has emerged in
the last decades.5,6 Resistance to fluoroquinolone (FQ) in
GBS was first described in Japan in 2003 and then it became
a growing problem.7 However, reports describing the increase
of resistance rates to FQs in GBS are scarce, especially in
isolates recovered from invasive infections. Resistance has
been documented in Spain, United States of America, and
Taiwan, but the highest levels of rates were found in
Korea.8–11 In Argentina, FQ resistance in GBS was first
reported after a national surveillance study of noninvasive
infections performed between 2005 and 2007; the preva-
lence of FQ resistance was 0.9%.12 In other countries of
Latin America, similar studies found low FQ resistance
levels.5,13
The major mechanism of FQ resistance among GBS is
related to point mutations acquired through a stepwise
process in the quinolone resistance-determining region
(QRDR) of gyrA and parC genes, which encode DNA
gyrase and topoisomerase IV. These substitutions weaken
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the interaction between quinolones and enzymes. The parC
gene is the primary target, which substantially increases the
probability of a second mutation in gyrA, resulting in high-
level quinolone resistance.10 Frequently described mutations
in parC are S79Y and S79F and in gyrA occurring pre-
dominantly at amino acid position 81 (S81L).9 Infrequently,
active efflux was described in GBS isolates with no muta-
tions in the QRDRs.14
In the context of a national, prospective multicenter study
of invasive infections of GBS, our purpose was to determine
the local prevalence of FQ resistance. In addition, we sought
to comprehensively characterize mechanisms of resistance,




A prospective observational study was designed to
evaluate the prevalence and phenotypic and molecular
features of FQ-resistant GBS isolates recovered from pa-
tients suffering from invasive disease caused by S. aga-
lactiae. This study was accomplished during one complete
year, from July 1, 2014, to June 30, 2015, in 86 health care
centers from 32 Argentinean cities. Ethical approval was
provided by the Ethics Committee of the Faculty of
Pharmacy and Biochemistry, Universidad de Buenos
Aires, Res (D) N4467/14.
Antibiotic and susceptibility tests
A five-disc scheme was designed using levofloxacin
(LVX 5-mg discs), ciprofloxacin (CIP 5-mg discs), nor-
floxacin (NOR 10-mg discs), ofloxacin (5-mg discs), and
pefloxacin (PF 5-mg discs) based on the Clinical and La-
boratory Standards Institute (CLSI) and Société Française
de Microbiologie recommendations.15,16 The use of PF was
included as it was proposed by Varon et al., and the com-
bination of discs allows to predict the presence of gyrA and
parC mutations.17 The minimal inhibitory concentration
(MIC) of LVX was determined by the agar dilution method.
PEN (10-mg discs), erythromycin (15-mg discs), clindamycin
(2-mg discs), and aminoglycosides (Streptomycin 300-mg
and Gentamicin 120-mg discs to detect high-level resistance)
were tested by the disc diffusion method.15
Amplification and sequencing of gyrA
and parC fragments
Amplification and sequencing of internal regions of gyrA
and parC genes were accomplished as described else-
where.6 Analysis of deduced amino acid sequences was
performed using the software Vector NTI Express, In-
forMax Inc. The S. agalactiae strain GD201008-001 (Ac-
cession number: cp003810.1 GenBank: https://ncbi.nlm
.nih.gov/nuccore/cp003810.1) was used as a reference
strain for comparative analysis.
Typing
Capsular typing was done using the Strep-B Kit (Statens
Serum Institut, Copenhagen, Denmark). Pulsed-field gel
electrophoresis (PFGE) was performed as it was described
previously using ApaI, with minor modifications.18 Com-
parison of fingerprints was carried out by the unweighted
pair-group method applying the Dice correlation coefficient.
A similarity of 80% was used to define a PFGE group and
with this cutoff value, profiles with differences in 1–6 bands
were assigned to the same clonal type and coded with
capital letters. Multilocus sequence typing (MLST) was
performed as described elsewhere (http://pubmlst.org/
sagalactiae).
Results
A total of 162 isolates were recovered from invasive in-
fections. According to the CLSI breakpoint, the resistance
rate to LVX was 14.8%.15 By the five-disc method, 24
isolates exhibited no inhibition zones to all tested FQs. One
isolate, denominated GBS30, showed no inhibition zones to
NOR and PF discs. The MIC range of LVX for the afore-
mentioned isolates (24/25) was 16–32 mg/L and the MIC
value for GBS30 was 1 mg/L.
In this study, resistant isolates proceeded from 13 dif-
ferent health care centers sited in 10 cities from 7 provinces
across the country. The analysis of epidemiological data
(Table 1) showed that 16 isolates were recovered from adult
women. Eleven of them had at least one underlying condi-
tion and diabetes mellitus was the most frequent one.
Moreover, 11/23 adults reported previous antibiotic use
during the 10-day period before GBS infection was con-
firmed. In six of these eleven cases, CIP was employed.
Only two isolates proceeded from early onset neonatal
sepsis (24 and 48 h after birth, respectively). Nine of twenty-
five isolates were recovered from skin or soft tissue infec-
tions and 8/25 from bacteremia.
All resistant isolates had amino acid changes within the
QRDRs of gyrA and parC compared with the reference
sequence. The mutations were S79F (23/24) or S79Y (1/24)
in the product of parC and S81L in the product of gyrA (24/
24). The LVX MIC range of 16–32 mg/L was associated
with the presence of double mutations. The GBS30 strain
exhibited a single-nucleotide substitution exclusively in
parC, resulting in S79C change. To our knowledge, this is
the first description of this novel mutation in the S. aga-
lactiae parC gene. Moreover, several silent base substitu-
tions, especially in parC, were detected (data not shown).
All isolates were susceptible to penicillin. Coresistance to
macrolides was found in three isolates (Table 1).
Serotype Ib was prevalent among FQ-resistant isolates
(22/25, 88%), followed by V (8%) and III (4%).
By PFGE, five major types were defined, type A ac-
counted for 84% of isolates (21/25). The remaining four
isolates presented unrelated profiles (designated as type B to
E). All PFGE type A isolates belonged to serotype Ib and
were recovered from 12 hospitals distributed in nine dif-
ferent cities of Argentina. The isolates included in PFGE
types D and E, GBS25 and GBS30, respectively, belonged
to serotype V. One representative isolate from PFGE type A
was studied by MLST and it belonged to sequence type 10.
Discussion
The rate of FQ resistance recorded in this study (14.8%)
is higher than the latest reports from our country and even
those from other countries of Latin America and the rest of











































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































the world, except Korea.9,12 Differences in antibiotic use
might be the major factors contributing to geographic dif-
ferences in FQ resistance.
According to the CLSI interpretative breakpoint, the
isolate GBS30 is categorized as susceptible. However, the
absence of an inhibition zone around the disc of NOR in-
dicates that it should be interpreted as decreased suscepti-
bility with the remark that there is a high risk of clinical
failure due to in vivo selection of FQ-resistant mutants.16
The scheme of five discs was able to detect GBS30, with no
inhibition zones to two FQs (NOR and PF) and exhibiting a
single-nucleotide substitution exclusively in parC. The lack
of an inhibition zone could represent an alert of first-step
mutation and also a high risk to select an FQ-resistant mu-
tant in vivo, with consequent treatment failure. The use of a
10-mg NOR disc test as a surrogate marker, by which to
detect low-level FQ-resistant mutants harboring only to-
poisomerase IV mutations, was previously proposed in S.
pneumoniae.17 Herein, we demonstrate that this strategy
could detect a GBS single-step mutant in parC.
Serotype Ib was the most frequent serotype among FQ-
resistant isolates. Considering the entire collection of 162
invasive isolates, serotypes Ia and Ib were more frequent
(28.4% and 28.4%, respectively, data not shown). Moreover,
serotype distribution in FQ-resistant isolates is significantly
different from the rest of the isolates that were susceptible to
FQ ( p < 0.005, chi-square analysis).
Reduced susceptibility to penicillin among FQ-resistant
GBS isolates was described by Kimura et al., but in our
collection, all FQ-resistant isolates were susceptible to
penicillin.19
In this study, as described by other authors, the relationship
between the serotype and PFGE profiles was detected.5 The
prevalence of clonal complex 10 among LVX-resistant
S. agalactiae was previously reported in Korea9 and Japan.20
In conclusion, the increase in FQ resistance may be
explained by dissemination of a single clone serotype Ib
that accounts for 84% of the GBS FQ-resistant isolates.
Our results emphasize the need for careful epidemiologic
investigation. Furthermore, this study reinforces the im-
portance of monitoring antibiotic susceptibility to quino-
lones. The inadvertent consequences of the use of FQs,
particularly for treatment of urinary tract infections, may
contribute to selection of resistant strains, especially con-
sidering that GBS is a frequent uropathogen.
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